Drugs / DNA neoantigen vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07587827 Background | Nov 2026 → May 2027 expected | colorectal cancer, malignant pancreatic neoplasm | Centre Georges Francois Leclerc | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DNA neoantigen vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07587827 ↗ |
| Modality | Vaccine | “composed of DNA neoantigen vaccine, Modified Vaccinia virus Ankara (MVA) viral adjuvant and anti-CTLA4 (ipilimumab)” NCT07587827 ↗ |
| Route | Intramuscular | “DNA vaccine 4 mg IM” NCT07587827 ↗ |